Day: December 23, 2021

LAS VEGAS, Dec. 23, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Golden Triangle Ventures, Inc. (OTC PINK:GTVH) (the “Company”) is pleased to announce a full list of the Company’s 2021 accomplishments and achievements, and provide insight into some of the overarching objectives that have been set in place for 2022. Golden Triangle Ventures has a mission to develop a portfolio of exciting businesses that synergistically benefit its core divisions which operate in the Health, Entertainment, and Technology sectors. Listed below is an overview of the projects that have unfolded, and the milestones accomplished during the past year as well as a transparent look at the future ahead.  After a strong year of developing the roadmap that set Golden Triangle Venture’s current and future course during the pandemic and shutdown in 2020,...

BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to become the General Counsel at Bruker Corporation, a global, publicly traded developer, manufacturer, and distributor of scientific instruments and analytical and diagnostic solutions. As a result, the Company’s Board of Directors has begun a search to appoint a successor to Mr. Alldredge, with a further announcement to be made in due course. Mr. Alldredge has agreed to work with the Company as an advisor to help achieve a smooth transition. “Since joining Conformis in 2019, Brent has been a trusted advisor and valued member of the executive management team. His new position at a multi-billion...

HINGHAM, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect its Intellectual Property. “2021 has been an extremely successful year for our LIBERTY Robotic System – key patents and development progress leading to the recently announced design freeze – so we remain bullish on our future prospects and maintaining the positive momentum,” commented Harel Gadot, CEO, President and Chairman. “The IP and R&D teams are accomplishing...

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022. Participation and presentation details are below:LifeSci Partners Corporate Access Event:Kathy Lee-Sepsick, President, Chief Executive Officer and Founder, will present on a panel entitled, “The Role of Gender Equality in Changing the Landscape of Life Sciences Innovation & Investment” on Thursday,...

– Topline results from pivotal SEAL study expected in Q1 2022 – If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. 23, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that the last patient has completed their final visit in the pivotal SEAL intranasal abuse study evaluating ADAIR1, a proprietary abuse-deterrent formulation of immediate-release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The SEAL study (Study to Evaluate the Abuse Liability,...

Researchers around the world can utilize the synthetic genome to produce virus to test strain-specific diagnostics, monoclonal antibody treatments, small-molecule therapies, or new vaccines against the highly transmissible variant SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the highly mutated and contagious Omicron variant (B.1.1.529 lineage). Omicron has been identified as a Variant of Concern by WHO and is spreading more rapidly than any other previous variant of SARS-CoV-2. The genome was built with the company’s BioXp™ 3250 system, a fully automated synthetic biology benchtop workstation for rapid, accurate, and reproducible writing of DNA and...

CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for hospitalized COVID New York, NY, and Tel Aviv, ISRAEL, Dec. 23, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Yahoo Finance Live with Akiko Fujita at 12:10 PM Eastern Time today. Mr. Commissiong will discuss the current state of COVID testing as well as emerging COVID antiviral pills, including Pfizer’s Paxlovid that recently received Emergency Use Authorization for the At-Home Treatment of mild to moderate COVID-19, and the Company’s Tollovir™ for hospitalized COVID patients. The...

To Nasdaq Copenhagen 23 December 2021 FIXING OF COUPON RATES         Fixing of coupon rates effective from 1 January 2022 Effective from 1 January 2022, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted. Bonds with semi-annual interest rate fixingThe new coupon rates will apply from 1 January 2022 to 30 June 2022: Uncapped bondsDK0009508319, (32G), maturity in 2022, new rate as at 1 January 2022: -0.1926% paDK0009520017, (32H), maturity in 2023, new rate as at 1 January 2022: -0.1825% paDK0009521338, (32G), maturity in 2023, new rate as at 1 January 2022: -0.1724% pa Bonds with quarterly interest rate fixingThe new coupon rates will apply from 1 January 2022 to 31 March 2022: Uncapped bondsDK0009512428, (22H), maturity in 2023, new rate as at 1 January 2022: 0.0620% paDK0009516411, (32H), maturity...